.jpeg)
Featured
boursenews.ma•Nov 12, 2026
Laprophan Unveils $37M State-of-the-Art Injectable Manufacturing Facility Ahead of IPO
Read More
Stay ahead of the market with our curated AI-powered financial news and expert analysis.
Laprophan is orchestrating a strategic reorganization of its pharmaceutical operations through its wholly-owned subsidiary Amanys Pharma. The company plans to gradually relocate antibiotic and injectable production from Casablanca to its Aïn El Aouda complex between 2027 and 2029, requiring an inves...